The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwCLL 2023 | Treatment approaches for patients with TP53-mutated MCL
In this interview, Thomas Lew, MBBS(Hons), Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Victoria, Australia, outlines the treatment approaches for patients with TP53-mutated mantle cell lymphoma (MCL), a particularly adverse disease subgroup in which conventional therapies, such as autologous stem cell transplants, are not effective. Dr Lew believes that allogeneic stem cell transplantation would be a better treatment approach, based on the durable remissions achieved in a small cohort of patients with TP53-mutated MCL treated with this therapy in the Peter MacCallum Cancer Centre and Royal Melbourne Hospital. He also examines the complex question of whether patients with this disease subgroups should be treated with allogeneic stem cell transplantation or CAR T-cell therapy as a first response and emphasizes the importance of testing newly diagnosed MCL patients for TP53 mutation. This interview was recorded at the biennial International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2023 meeting, held in Boston, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
